MARKET

APLT

APLT

Applied
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.26
+0.16
+0.84%
Opening 09:31 07/26 EDT
OPEN
19.26
PREV CLOSE
19.10
HIGH
19.26
LOW
19.26
VOLUME
1.54K
TURNOVER
--
52 WEEK HIGH
33.34
52 WEEK LOW
13.58
MARKET CAP
502.33M
P/E (TTM)
-4.1353
1D
5D
1M
3M
1Y
5Y
61 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.
Benzinga · 06/29 08:58
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers
Benzinga · 06/28 16:32
BRIEF-Applied Therapeutics Added To Russell Microcap® Index
reuters.com · 06/28 12:44
Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today
Benzinga · 06/25 16:07
BRIEF-Applied Therapeutics Granted Fast Track Designation By FDA For AT-007 For Galactosemia
reuters.com · 06/17 11:50
Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder
syahrir maulana/iStock via Getty Images Applied Therapeutics (APLT) has added ~6.8% in the pre-market after the company announced that the FDA has granted the Fast Track designation to AT-007 for the treatment
Seekingalpha · 06/17 11:41
Applied Therapeutics Stock Moves Higher On FDA Fast Track Review For AT-007 In Rare Metabolic Disorder
Benzinga · 06/17 11:18
Applied Therapeutics Gets FDA Fast Track Designation for Potential Galactosemia Drug; Shares Gain Pre-Bell
MT Newswires · 06/17 07:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APLT. Analyze the recent business situations of Applied through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APLT stock price target is 44.50 with a high estimate of 85.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 93
Institutional Holdings: 15.82M
% Owned: 60.67%
Shares Outstanding: 26.08M
TypeInstitutionsShares
Increased
36
2.79M
New
4
127.55K
Decreased
14
136.53K
Sold Out
4
65.87K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.09%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
Shoshana Shendelman
Chief Financial Officer
Charles Silberstein
Other
Adam Hansard
Other
Riccardo Perfetti
Lead Director/Independent Director
Teena Lerner
Independent Director
Leslie Funtleyder
Independent Director
Stacy Kanter
Independent Director
Joel Marcus
Independent Director
Jay Skyler
No Data
About APLT
Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway, an alternative glucose metabolism pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. Its other product candidates include AT-007, AT-003 and AT-104. AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR).

Webull offers kinds of Applied Therapeutics Inc stock information, including NASDAQ:APLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APLT stock methods without spending real money on the virtual paper trading platform.